Novartis has been granted a patent for the use of mavoglurant in reducing cocaine use, preventing relapse, promoting abstinence, and treating symptoms of depression or anxiety in patients with cocaine use disorder. The method involves administering 200mg of mavoglurant twice daily to achieve these effects. GlobalData’s report on Novartis gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Novartis AG - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Novartis, Cancer treatment biomarkers was a key innovation area identified from patents. Novartis's grant share as of January 2024 was 51%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of cocaine use disorder using mavoglurant

Source: United States Patent and Trademark Office (USPTO). Credit: Novartis AG

A recently granted patent (Publication Number: US11878001B2) discloses a method for reducing cocaine use in patients with cocaine use disorder by administering mavoglurant or a pharmaceutically acceptable salt thereof. The method involves administering mavoglurant at a specific dosage of 200 mg/b.i.d., resulting in a reduction in the amount and/or frequency of cocaine use by the patient. The patent also covers the administration of mavoglurant in combination with standardized psychological treatment, psychosocial or behavioral therapy, computer-assisted therapy, methadone or buprenorphine treatment, and other active agents.

Furthermore, the patent includes provisions for patients with comorbid psychiatric disorders such as antisocial personality disorder, depression, anxiety, schizophrenia, and others. It also accounts for patients with genetic variations associated with substance use disorders or specifically cocaine use disorder. The method allows for the administration of mavoglurant in immediate-release or modified-release forms, along with contingency management-based therapy. Overall, the patent outlines a comprehensive approach to addressing cocaine use disorder by combining pharmacological intervention with various therapeutic modalities tailored to individual patient needs and characteristics.

To know more about GlobalData’s detailed insights on Novartis, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies